Bacterial polyphenol extract from Bacillus DO-R5 fights gout by blocking enzyme

Gout, a form of inflammatory arthritis driven by the accumulation of uric acid in the blood and the deposition of sharp monosodium urate crystals in the joints, is rising steadily worldwide, particularly in developing countries undergoing rapid lifestyle transitions. Current treatments such as allopurinol and febuxostat can lower urate levels, while nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids manage flares, but their long-term use is frequently limited by hepatotoxicity, nephrotoxicity, gastrointestinal disturbances, immunosuppression, and increased cardiovascular risk. Now, a research team from Vietnam has reported that a polyphenol- and flavonoid-rich extract derived from an endophytic bacterium may rival the gold-standard drug allopurinol at lowering uric acid in mice, while simultaneously dampening inflammation and pain, according to a new open-access study published in Current Research in Biotechnology.

The bacterium at the heart of the work, Bacillus sp. DO-R5, is no ordinary microbe. It is an endophytic, Gram-positive, spore-forming strain originally isolated from the root of Dillenia ovata in An Giang Province, Vietnam, an ecological niche whose microbial inhabitants have proven to be rich sources of bioactive secondary metabolites. When cultured in optimized fermentation conditions in potato dextrose broth supplemented with d-glucose at 38 °C, pH 7.5, for approximately 70 hours, the strain secrets an arsenal of phenolic and flavonoid compounds into its culture medium. The researchers collected the cell-free supernatant by centrifugation and extracted its active constituents with ethyl acetate to obtain what they call oDO-R5e, an optimized extract previously characterized by HPLC as containing gallic acid, chlorogenic acid, vanillic acid, caffeic acid, quercetin, and kaempferol, among other compounds.

The scientific logic of the study rests on a well-established biochemical bottleneck. Xanthine oxidase (XO) is the enzyme that catalyzes the final two steps of purine catabolism, oxidizing hypoxanthine to xanthine and then xanthine to uric acid. Blocking this enzyme, as allopurinol does, reduces urate production at its source. In vitro, the Vietnamese team screened 19 endophytic bacterial strains from D. ovata and found that DO-R5 produced by far the highest content of XO-inhibitory compounds, measuring 17.41 milligrams of allopurinol equivalents per milliliter of cell-free supernatant, well above the roughly 10 to 12 mg AE/mL recorded by its closest competitors. When the team compared the crude and optimized extracts, the results were striking: the optimized oDO-R5e inhibited XO with an IC50 of just 6.66 micrograms per milliliter, 3.74 times more potent than the crude preparation and strong enough to place the extract, by the authors’ own proposed classification system, among the “very strong” XO inhibitors, surpassing most plant extracts previously reported in the literature, including Alocasia longiloba and Agastache rugosa.

To probe the molecular mechanism, the researchers turned to computational molecular docking against the crystal structure of bovine xanthine oxidase from the Protein Data Bank. After preparing the protein with AutoDockTools and energy-minimizing the six representative phenolic ligands at the density functional theory level using the B3LYP functional and a 6-31G(d,p) basis set, the team ran docking simulations with AutoDock Vina inside PyRx. All six plant-like compounds settled deep into the catalytic pocket, forming hydrogen bonds with Arg880 and Glu802, two residues directly involved in catalysis, and hydrophobic Pi-interactions with the gatekeeper residues Phe914, Phe1009, and Val1011, a binding pattern closely mirroring that of allopurinol itself. Remarkably, most of the natural compounds outperformed the standard drug computationally: chlorogenic acid posted the strongest binding energy at −8.0 kcal/mol, compared with −6.9 kcal/mol for allopurinol, followed by quercetin at −7.6, caffeic acid at −7.4, kaempferol at −7.3, and gallic acid at −7.1 kcal/mol. Only vanillic acid, whose compact structure limits steric hindrance within the pocket, fell short at −5.5 kcal/mol.

The in vitro and in silico evidence set the stage for the study’s central question: does the extract actually work in a living animal? Using healthy adult male albino mice, with all experiments approved by the Animal Ethics Committee of Can Tho University, the researchers induced acute hyperuricemia with an intraperitoneal injection of potassium oxonate, a uricase inhibitor that pushes serum uric acid from a normal 3.93 mg/dL up to 7.14 mg/dL. Mice receiving oDO-R5e orally for seven consecutive days showed a clear dose-dependent response. At 100 mg/kg body weight, the effect was modest, reducing uric acid to 5.99 mg/dL, a 31 percent efficacy. At 200 mg/kg, serum urate fell to 4.09 mg/dL, an efficacy approaching 80 percent. But at 400 mg/kg, the extract brought uric acid back to 3.03 mg/dL, corresponding to 106.94 percent efficacy, statistically indistinguishable from allopurinol at 30 mg/kg.

Crucially, the hyperuricemia model also inflicts collateral oxidative damage, and here the extract delivered a second therapeutic dividend. Potassium oxonate injection caused hepatic malondialdehyde, a lipid peroxidation marker, to soar from 15.09 to 74.33 nM per gram of tissue, while kidney MDA rose from 12.89 to 77.30 nM/g, and the master intracellular antioxidant glutathione collapsed in both organs, falling to roughly 30 nM/g in liver and 61 nM/g in kidney. Treatment with oDO-R5e reversed this cascade in a dose-dependent fashion: at 400 mg/kg, liver MDA dropped to 10.37 nM/g and kidney MDA to 14.96 nM/g, both below normal levels, while glutathione rebounded to 289.45 nM/g in liver and 321.27 nM/g in kidney, exceeding the healthy control values. The authors interpret this dual action, urate lowering plus antioxidant restoration, as evidence that the extract’s polyphenols and flavonoids act not only on XO but also on the broader redox environment of hepatic and renal tissue, a property of particular value in a disease where oxidative stress contributes to organ damage beyond the joints.

Anti-inflammatory efficacy was assessed in the classical carrageenan-induced paw edema model, in which subcutaneous injection of the polysaccharide into the hind paw triggers a two-phase inflammatory response mediated first by histamine, serotonin, and bradykinin, and later by prostaglandins and the cytokines TNF-α and IL-1β. Untreated mice developed edema peaking at 75.10 percent three hours after injection and remaining near 73 percent after 24 hours. oDO-R5e suppressed the swelling in a dose-dependent manner: at 200 mg/kg, edema fell to 44.02 percent at three hours and 36.13 percent at 24 hours, a performance comparable with the reference drug diclofenac at 10 mg/kg. At 400 mg/kg, the effect was sustained through the late phase, and the authors conclude that the 200 to 400 mg/kg window represents an optimal therapeutic range, balancing efficacy against dose saturation.

Pain relief, the third pillar of gout management, was tested using the acetic acid-induced writhing assay, in which intraperitoneal acetic acid releases prostaglandins that stimulate sensory nerve endings, causing characteristic abdominal contractions. Untreated mice averaged more than 17 writhing episodes during the peak 10-to-15-minute window. At 200 mg/kg, oDO-R5e cut this to 8.29 episodes, roughly a 50 percent reduction, and virtually abolished writhing by the end of the observation period, matching diclofenac’s performance. At 400 mg/kg the analgesic effect plateaued, mirroring the pattern seen in the inflammation model and suggesting that the extract’s active constituents may relieve pain both by suppressing prostaglandin synthesis and by neutralizing the free radicals that sensitize peripheral nociceptors.

Taken together, the study sketches a coherent, multitarget profile for a single microbial extract: it inhibits the enzyme that generates uric acid, computationally and biochemically; it protects the liver and kidneys from the oxidative fallout of hyperuricemia; it suppresses acute inflammatory cascades; and it blunts inflammatory pain. The authors suggest that the synergy among oDO-R5e’s constituents, which include flavonoids known to bind the molybdenum-pterin catalytic center of XO and phenolic acids capable of hydrogen bonding around the active site, could also intersect with the NLRP3 inflammasome pathway, the central inflammatory switch in gout pathogenesis, though this remains to be tested directly. Because the extract originates from an endophytic bacterium that can be grown in fermentation tanks rather than harvested from rare plants, its production is potentially sustainable and scalable, an advantage for any future phytomedicine-style development.

The road from a mouse study to a gout prescription is long. The authors themselves caution that deeper molecular pathway studies, long-term toxicity evaluation, and combination studies with existing drugs will be needed before oDO-R5e, or standardized fractions of it, can enter clinical development. Even so, the convergence of strong in vitro enzyme inhibition, supportive computational docking, and in vivo efficacy rivaling allopurinol represents an unusually complete preclinical package for a bacterially derived natural product. As gout prevalence climbs globally in tandem with obesity, purine-rich diets, and metabolic syndrome, and as patients increasingly struggle with the side-effect burden of lifelong urate-lowering therapy, the idea that a soil-dwelling endophyte from a Vietnamese river delta might one day supply a safer, multitarget alternative is a proposition that clinicians and patients alike will be watching closely.